Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Total Non-Current Liabilities (2020 - 2025)

Apellis Pharmaceuticals (APLS) has 6 years of Total Non-Current Liabilities data on record, last reported at $697.2 million in Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities rose 7.5% year-over-year to $697.2 million; the TTM value through Dec 2025 reached $697.2 million, up 7.5%, while the annual FY2025 figure was $697.2 million, 7.5% up from the prior year.
  • Total Non-Current Liabilities reached $697.2 million in Q4 2025 per APLS's latest filing, up from $654.3 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $697.2 million in Q4 2025 and bottomed at $302.0 million in Q3 2021.
  • Average Total Non-Current Liabilities over 5 years is $583.0 million, with a median of $591.9 million recorded in 2023.
  • The widest YoY moves for Total Non-Current Liabilities: up 136.93% in 2021, down 32.73% in 2021.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $338.0 million in 2021, then surged by 66.75% to $563.5 million in 2022, then grew by 5.03% to $591.9 million in 2023, then increased by 9.57% to $648.5 million in 2024, then grew by 7.5% to $697.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Non-Current Liabilities were $697.2 million in Q4 2025, $654.3 million in Q3 2025, and $663.0 million in Q2 2025.